A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

The impact of digital health technologies on tuberculosis treatment: a systematic review

(2018) Brian Kermu Ngwatu et al.   EUROPEAN RESPIRATORY JOURNAL

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model

(2017) Emily A. Kendall et al.   PLOS MEDICINE

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

(2016) Payam Nahid et al.   CLINICAL INFECTIOUS DISEASES

Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis

(2016) N. Alipanah et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors

(2016) Darren B. Taichman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

(2014) Corinne S. Merle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

(2014) Stephen H. Gillespie et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

(2014) Amina Jindani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen

(2014) Kyung-Wook Jo et al.   RESPIRATORY MEDICINE

Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion

(2009) John L. Johnson et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE